Xiaomin Ou

Publications : 43
Aldex : 30
H-index : 10
Citations : 314

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Xiayun He, Yu Wang et 2 al.

Jun 12, 2022 in ClinicalTrials.gov
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) followed by radiotherapy improve progression-free survival, for patients with unresectable laryngeal/hypopharyngeal carcinoma.

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

Xiayun He, Yu Wang et 2 al.

Jul 25, 2021 in ClinicalTrials.gov
The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Chaosu Hu, Xiaomin Ou

Jul 25, 2021 in ClinicalTrials.gov
The aim of this study is to define the efficacy and safety of Fluzoparib and Camrelizumab in treating patients with recurrent/metastatic nasopharyngeal carcinoma that progressed after first-line chemotherapy.

Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal Carcinoma

Xiayun He, Xiaomin Ou

Mar 29, 2018 in ClinicalTrials.gov
Radiation-associated carotid vasculopathy is a common late sequelae in patients with head and neck cancer, which correlates with the incidence of stroke. Currently, little is known about the incidence of radiation-associated carotid vasculopahty in the context of intensity-modulated radiation therapy (IMRT). The aim of this study is to determine whether IMRT will increase the incidence of carotid ...

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Chaosu Hu, Chao-Su Hu et 3 al.

Jun 11, 2022 in ClinicalTrials.gov
Nasopharyngeal carcinoma is biologically different from traditional head and neck squamous cell carcinoma. The mainstay treatment for locally advanced nasopharyngeal carcinoma is cisplatin-based concurrent chemoradiation. Recent phase III randomized control trials have demonstrated that induction chemotherapy plus concurrent chemoradiation further improved progression-free survival. However, not e...

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Xiaomin Ou, Chaosu Hu

Jul 31, 2020 in ClinicalTrials.gov
The aim of this study is to compare the efficacy of Toripalimab Combined with GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic NPC.

oncology

Cancers, Vol. 14, Pages 5583: Postoperative Chemoradiotherapy versus Radiotherapy Alone in Major Salivary Gland Cancers: A Stratified Study Based on the External Validation of the Distant Metastasis Risk Score Model

Wenbin Yan, Chaosu Hu et 5 al.

Nov 14, 2022 in Cancers
Cancers, Vol. 14, Pages 5583: Postoperative Chemoradiotherapy versus Radiotherapy Alone in Major Salivary Gland Cancers: A Stratified Study Based on the External Validation of the Distant Metastasis Risk Score Model Cancers doi: 10.3390/cancers14225583 Authors: Wenbin Yan Lili Huang Jianyun Jiang Chunying Shen Xiaomin Ou Chaosu Hu Background : The role of additional chemoradiotherapy (CRT) for di...

Structure of the mitochondrial TIM22 complex from yeast.

Yutong Zhang, Long Li et 7 al.

Sep 11, 2020 in Cell research

The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings.

Bingxin Gu, Shaoli Song et 8 al.

Sep 30, 2021 in Journal of nuclear medicine
18F-FDG PET/CT plays an important role in locating the primary tumor for patients with head and neck cancer of unknown primary (HNCUP). Nevertheless, in some cases it can be challenging to locate the primary malignancy on 18F-FDG PET/CT scans. Because 68Ga-radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT has promising results in detecting different tumor entities, our study aimed...

cancer

A nomogram involving immune‐inflammation index for predicting distant metastasis‐free survival of major salivary gland carcinoma following postoperative radiotherapy

Wenbin Yan, Chaosu Hu et 3 al.

Sep 1, 2022 in Cancer Medicine
The nomogram predicting distant metastasis free survival(DMFS) based on the clinicopathological factors and immune inflammation index for the major salivary gland carcinoma. Background Postoperative radiotherapy (PORT) is beneficial in the improvement of local regional control and overall survival (OS) for major salivary gland carcinomas (SGCs), and distant metastasis remained the main failure...

Similar author:

Olivier Lesens